Loading
Yanuki
ARTICLE DETAIL
Hologic to Be Acquired by Blackstone and TPG for Up to $79 Per Share | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | Hologic to Be Acquired by Blackstone and TPG for Up to $79 Per Share | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026

Finance / Mergers and Acquisitions

Hologic to Be Acquired by Blackstone and TPG for Up to $79 Per Share

Hologic, Inc. (Nasdaq: HOLX) has announced its acquisition by funds managed by Blackstone and TPG in a deal valued at up to $79 per share, translating to an enterprise value of up to $18.3 billion. This acquisition aims to bolster Hologic's...

Blackstone and TPG Agree to $18 Billion Deal to Buy Hologic
Share
X LinkedIn

hologic
Hologic to Be Acquired by Blackstone and TPG for Up to $79 Per Share Image via Bloomberg.com

Key Insights

  • Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, plus a non-tradable contingent value right (CVR) to receive up to $3 per share based on the achievement of certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.
  • The purchase price represents a premium of approximately 46% to Hologic’s closing price on May 23, 2025, before media reports of a possible transaction.
  • The transaction includes significant minority investments from ADIA and GIC.
  • Stephen P. MacMillan, Hologic’s Chairman, President, and CEO, views this as an exciting new chapter, leveraging Blackstone and TPG's resources and expertise to enhance the company's ability to deliver critical medical technologies.

In-Depth Analysis

The acquisition is structured such that Hologic stockholders will receive $76 per share in cash, along with a contingent value right (CVR) that could add up to $3 per share. These CVR payments are tied to Hologic’s Breast Health business achieving specific revenue targets in fiscal years 2026 and 2027.

This deal is expected to close in the first half of calendar year 2026, pending Hologic’s stockholders' approval, regulatory approvals, and other customary closing conditions. Upon completion, Hologic’s common stock will be delisted from the Nasdaq stock market, though the company will maintain its headquarters in Marlborough, Massachusetts, and continue to operate under the Hologic name.

The merger agreement also includes a 45-day 'go-shop' period, allowing Hologic to solicit alternative acquisition proposals. Goldman Sachs & Co. LLC is serving as the financial advisor to Hologic, while Citi is advising the Blackstone-and-TPG consortium.

Read source article

FAQ

What does the acquisition mean for Hologic stockholders?

Hologic stockholders will receive $76 per share in cash, plus a contingent value right of up to $3 per share based on revenue milestones.

When is the acquisition expected to close?

The transaction is expected to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals.

Will Hologic continue to operate under the same name?

Yes, Hologic will maintain its headquarters and continue to operate under the Hologic name and brand.

Takeaways

  • Hologic is being acquired by Blackstone and TPG for up to $79 per share.
  • The acquisition aims to strengthen Hologic's position in women’s health and accelerate growth.
  • Stockholders will receive $76 per share plus a contingent value right tied to future revenue milestones.

Discussion

What are your thoughts on the potential impact of this acquisition on the future of women's health technologies? Share this article with others who need to stay ahead of this trend!

Sources

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.